Mus­tang Bio ven­tures in­to gene ther­a­py, li­cens­ing 'bub­ble boy dis­ease' treat­ment from St. Jude

When Mus­tang Bio $MBIO inked the lease deal for its Worces­ter, MA man­u­fac­tur­ing fa­cil­i­ty last year, CEO Man­ny Litch­man said a more cost ef­fec­tive man­u­fac­tur­ing ap­proach would lend a com­pet­i­tive edge to their ear­ly-stage CAR-T pro­grams. As it turns out, gene ther­a­py will al­so be part of that game plan.

Li­cens­ing from St. Jude Chil­dren’s Re­search Hos­pi­tal in Mem­phis, Mus­tang adds an ex vi­vo lentivi­ral gene ther­a­py to for one form of “bub­ble boy dis­ease” to its pipeline, which has up till now been stocked with can­cer-fight­ing cell ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER